Glycine Receptor Antibodies in Pediatric Patients with Facial Nerve Palsy

2021 ◽  
Author(s):  
Ch. Lechner ◽  
V. Endmayr ◽  
S. Hametner ◽  
C. Schwaiger ◽  
F. Deisenhammer ◽  
...  
Keyword(s):  
Facial Nerve ◽  
Nerve Palsy ◽  
Pediatric Patients ◽  
Facial Nerve Palsy ◽  
Glycine Receptor ◽  
Receptor Antibodies

scholarly journals Facial Nerve Palsy After Occipital Nerve Blocks — A Case Report

2021 ◽  
Author(s):  
Abdullah Shoaib
Keyword(s):  
Case Report ◽  
Peripheral Nerve ◽  
Facial Nerve ◽  
Nerve Palsy ◽  
Pediatric Patients ◽  
Facial Nerve Palsy ◽  
Rare Complication ◽  
Nerve Blocks ◽  
Peripheral Nerve Blocks ◽  
Occipital Nerve

The use of bupivacaine and other local anesthetics to perform peripheral nerve blocks is a mainstay in the management of refractory headaches and migraines. In this case report, a patient presented with transient facial nerve palsy shortly after receiving occipital nerve blocks for headaches. Patient’s symptoms self-resolved, and her symptoms were thought to be due to displacement and spreading of bupivacaine to the facial nerve. The spread of bupivacaine can be facilitated by tracking across fascial planes or nerve sheaths. Similar side effects have been seen in dental anesthesia, but there has only been one other report of such a presentation associated with occipital nerve blocks, and none in pediatric patients. Physicians should be aware of this rare complication with peripheral nerve blocks.

TRANSIENT FACIAL NERVE PALSY AFTER SCALP BLOCK FOR AWAKE CRANIOTOMY: A CASE REPORT

2018 ◽  
Vol 4 (5) ◽  
pp. 369-371
Author(s):  
Rajashree U Gandhe . ◽  
Chinmaya P Bhave . ◽  
Avinash S Kakde . ◽  
Neha T Gedam .
Keyword(s):  
Case Report ◽  
Facial Nerve ◽  
Nerve Palsy ◽  
Facial Nerve Palsy ◽  
Awake Craniotomy ◽  
Scalp Block

scholarly journals Facial nerve palsy as the presenting feature of metastatic prostatic cancer in the temporal bone

2020 ◽  
Vol 6 (1) ◽  
pp. 1-5
Author(s):  
Daichi Fujii ◽  
Hikari Shimoda ◽  
Natsumi Uehara ◽  
Takeshi Fujita ◽  
Masanori Teshima ◽  
...  
Keyword(s):  
Facial Nerve ◽  
Temporal Bone ◽  
Prostatic Cancer ◽  
Nerve Palsy ◽  
Facial Nerve Palsy ◽  
Metastatic Prostatic Cancer

scholarly journals HGG-48. ROS1 INHIBITOR ENTRECTINIB USE IN RELAPSE/REFRACTORY INFANTILE GLIOBLASTOMA WITH POSITIVE ROS1 FUSION - A CASE REPORT WITH PROMISING RESPONSE

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii352-iii352
Author(s):  
Dennis Tak-Loi Ku ◽  
Matthew Ming-Kong Shing ◽  
Godfrey Chi-Fung Chan ◽  
Eric Fu ◽  
Ping-Wa Yau ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Facial Nerve ◽  
Nerve Palsy ◽  
Facial Nerve Palsy ◽  
Tumour Progression ◽  
Molecular Study ◽  
Subtotal Resection ◽  
Residual Tumour ◽  
Molecular Assay ◽  
Debulking Surgery

Abstract INTRODUCTION Infantile glioblastoma is rare with poor prognosis. Recent molecular study for infantile hemispheric high grade glioma found its association with ALK/ROS1/NTRK/MET pathway. This suggested the potential use of targeted therapy for refractory / relapse patients. CASE: A newborn presented with apnea, CT brain showed intracranial haemorrhage. MRI then showed a left parietal tumour with bleeding and mass effect. Craniotomy achieved subtotal resection. Chemotherapy VCR/CPM alternating with CDDP/VP-16 was given for one year. Patient was stable with static residual tumour during chemotherapy. However patient developed status epilepticus two weeks after off treatment. MRI showed significant tumour progression which required 2nd & 3rd debulking surgery. Molecular assay by nanostring panel showed BRAF-KIAA1549 fusion. MEK inhibitor Trametinib was tried for 3 months and stopped as disease progression. Further molecular assay by RNASeq showed presence of ROS1 fusion (ZCCHC8-ROS1) while absent of BRAF fusion. Patient underwent 4th debulking surgery as impending herniation while waiting for the targeted therapy. It was complicated with right hemiplegia and facial nerve palsy postoperatively. Finally, ROS1 inhibitor Entrectinib was started 2 weeks later. It was well tolerated without significant adverse reaction. Patient made dramatic neurological recovery including improved facial nerve palsy, able to walk unaided and self feed. MRI brain 1 and 3 months after Entrectinib showed interval reduction in residual tumour. Patient is currently progression-free for 6 months. CONCLUSION Early molecular study for infantile glioblastoma is useful to guide novel therapy. Molecular result may varies between different panels or change over time, to be interpreted with caution.

scholarly journals A rare case of congenital facial nerve palsy with extreme ocular manifestations

2021 ◽  
Vol 14 (5) ◽  
pp. e242540
Author(s):  
Rahul Kumar Bafna ◽  
Suman Lata ◽  
Anusha Sachan ◽  
Mohamed Ibrahime Asif
Keyword(s):  
Facial Nerve ◽  
Rare Case ◽  
Nerve Palsy ◽  
Facial Nerve Palsy ◽  
Ocular Manifestations

scholarly journals Erratum: Neonatal Cerebellar Hemorrhage and Facial Nerve Palsy: An Unusual Association

2020 ◽  
Vol 10 (03) ◽  
pp. e1-e1
Author(s):  
Caterina Coviello ◽  
Giulia Remaschi ◽  
Sabrina Becciani ◽  
Simona Montano ◽  
Iuri Corsini ◽  
...  
Keyword(s):  
Facial Nerve ◽  
Nerve Palsy ◽  
Facial Nerve Palsy ◽  
Cerebellar Hemorrhage ◽  
Unusual Association

Differential diagnosis of peripheral facial nerve palsy: a retrospective clinical, MRI and CSF-based study

2019 ◽  
Vol 266 (10) ◽  
pp. 2488-2494 ◽  
Author(s):  
Julia Zimmermann ◽  
Sarah Jesse ◽  
Jan Kassubek ◽  
Elmar Pinkhardt ◽  
Albert C. Ludolph
Keyword(s):  
Differential Diagnosis ◽  
Facial Nerve ◽  
Nerve Palsy ◽  
Facial Nerve Palsy ◽  
Peripheral Facial Nerve Palsy ◽  
Clinical Mri
Sign in / Sign up

Export Citation Format

Share Document